ORGANIZATION

• Sales by JCROA Member Companies Rise 4.9% to 143.5 Billion Yen in FY2014
  July 15, 2015

• “Humanitarian Trials” Hefty Burden on Drug Makers: JPMA Regulatory Head
  July 10, 2015

• JPMA Sacks Hasegawa as Vice President after Business Improvement Order
  July 3, 2015

• FPMAJ Chair Hails Innovation-Fueling Policies in Govt Fiscal Plan
  July 2, 2015

• JPMA Announces New Fair Competition Guidelines
  July 2, 2015

• JGSM Policy Proposal Calls for Generic Volume Target of 80% by End of FY2020
  July 1, 2015

• Dr Takaku Clinches Sixth Term as JAMS Chief
  June 26, 2015

• Chiba Univ. Hospital to Raise Generic Drug Use Rate to 80% after July: Director-General
  June 24, 2015

• FPMAJ Subcommittee Calls for Caution on “Simply Adding 2% to NHI Prices in Conjunction with Sales Tax Hike” in FY2017 Revision
  June 16, 2015

• FPMAJ to Present Evidence Showing Revenue from Premium for New Drug Development Is Being Invested in New Drugs
  June 16, 2015

• Industry Calls for Definition of “Basic Drugs”: FPMAJ Committee
  June 15, 2015

• EFPIA Japan Chief Frets Negative Market Growth amid Pressure on Drug Costs
  June 11, 2015

• Industry, Govt, Academia Should Discuss Challenges Facing Biosimilars: Prof. Kurokawa
  June 9, 2015

• PhRMA Chairman Says Budget Issues Controllable with Generics
  June 4, 2015

• JPMA to Draft Format of Application for Approval for Biopharmaceuticals
  June 4, 2015

• US, European Lobbies Set Out Healthcare Policy Proposals for Japan
  June 1, 2015

• JPWA Chief Suzuki Renews His Resolve as He Wins Second Term
  June 1, 2015

• JPMA Extends Suspension of Activities for Takeda as It Awaits Ruling of Administrative Authority on Blopress Scandal
  May 29, 2015

• Doctors Need to Be More Cost-Conscious When Prescribing: Dr Imamura of JMA
  May 29, 2015

• FPMAJ, JPMA, and JGA Call for “Balanced” Approach to Control Drug Expenditure in Joint Declaration
  May 28, 2015

ページ

• « 先頭
• ‹ Prev
• …
• 52
• 53
• 54
• 55
• 56
• 57
• 58
• 59
• 60
• …
• Next ›
• 最終 »